BC
SLNO

Bridgefront Capital’s Soleno Therapeutics SLNO Stock Holding History

Bridgefront Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,096
Closed -$293K – 832
2025
Q1 		$293K Buy
+4,096
New +$199K 0.08% 406

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bridgefront Capital's SLNO Position: Q2 2025 in Review

Bridgefront Capital sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 4,096 shares — an estimated $293K sold.

Bridgefront Capital first reported a position in SLNO in Q1 2025 and held it in 1 quarter. The position peaked at $293K in Q1 2025. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

  • Bridgefront Capital reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bridgefront Capital sold 4,096 Soleno Therapeutics shares in Q2 2025, an estimated $293K.
  • Bridgefront Capital first reported a position in Soleno Therapeutics in Q1 2025 and held it in 1 quarter.
  • Bridgefront Capital's Soleno Therapeutics position peaked at $293K in Q1 2025.
  • 233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.